Acumen Pharmaceuticals Inc ABOS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/16/24 EDT
3.73quote price arrow down-0.07 (-1.84%)
Volume
83,446
52 week range
1.81 - 11.31
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.73
  • 52 Week High11.31
  • 52 Week High Date07/17/23
  • 52 Week Low1.81
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap224.098M
  • Shares Out60.08M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change-2.86

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.73
  • 52 Week High11.31
  • 52 Week High Date07/17/23
  • 52 Week Low1.81
  • 52 Week Low Date11/10/23
  • Market Cap224.098M
  • Shares Out60.08M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change-2.86

RATIOS/PROFITABILITY

  • EPS (TTM)-1.05
  • P/E (TTM)-3.54
  • Fwd P/E (NTM)-3.33
  • EBITDA (TTM)-65.714M
  • ROE (TTM)-25.36%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-28,271.13%
  • Debt To Equity (MRQ)11.53%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Acumen Pharmaceuticals Inc

 

Profile

MORE
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is...
Daniel O'Connell
Chief Executive Officer, Director
James Doherty Ph.D.
President, Chief Development Officer
Russell Barton
Chief Operating Officer
W. Matthew Zuga
Chief Financial Officer, Chief Business Officer
Address
427 PARK ST.
Charlottesville, VA
22902
United States

Top Peers

SYMBOLLASTCHG%CHG
CRVO
CervoMed Inc
24.36-0.36-1.46%
PRLD
Prelude Therapeutics Inc
4.28+0.28+7.00%
INMB
INmune Bio Inc
11.17-0.19-1.67%
LENZ
LENZ Therapeutics Inc
16.53+0.69+4.36%
TRVI
Trevi Therapeutics Inc
2.84+0.07+2.71%